Dr. Reddy's Denies Report Of 25% Workforce Cost Cut, Calls News Factually Incorrect And Confirms No Disclosure-Worthy Event Under SEBI Regulations

Date: April 14, 2025 

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ) 
BSE Limited (Scrip Code: 500124) 
New York Stock Exchange Inc. (Stock Code: RDY) 
NSE IFSC Ltd (Stock Code: DRREDDY) 

Dear Sirs, 

Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015 – information on reported news item 

This is in reference to Regulation 30(11) of the SEBI (Listing Obligations and Disclosure Requirements) 
Regulations, 2015 ("SEBI Listing Regulations") regarding a news item published in Business Standard 
(newspaper/ media) on April 13, 2025, with the heading "DRL trims workforce costs by 25% amid 
Revlimid-linked margin strain". 

We wish to clarify that the said news is factually incorrect. We categorically deny the claim of a 25% 
workforce cost reduction and the other claims mentioned in the said news article. 

In this regard, please note that the Company does not comment on market speculations and there is 
currently no such event or information which requires a disclosure under Regulation 30 of the SEBI 
Listing Regulations. 

In compliance with Regulation 30 of the SEBI Listing Regulations, the Company makes prompt 
disclosure of any event or information, as and when any event or information is considered material or 
warrants such disclosure under the said Regulation. 


This is for your information. 

Thanking you. 

Yours faithfully, 
For Dr. Reddy's Laboratories Limited 

K Randhir Singh 
Company Secretary, Compliance Officer and Head-CSR 

Dr. Reddy's Laboratories Ltd. 
8-2-337, Road No. 3, Banjara Hills 
Hyderabad – 500 034, Telangana, India